Conatus Pharmaceuticals (CNAT) Tops Q2 EPS by 8c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38).

Cash, cash equivalents and marketable securities were $30.2 million at June 30, 2016, compared with $36.5 million at December 31, 2015. The company believes current financial resources are sufficient to maintain operations and ongoing clinical trials for at least the next 12 months.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results
• 374Water Inc (SCWO) Misses Q2 EPS by 15c